Targeting fundamentals of inflammation, autoimmunity and fibrosis

Granite Bio Debuts With $100 Million of Capital

–

Granite Bio Debuts With $100 Million of Capital –

  • TRANSFORM

    inflammatory, autoimmune and fibrotic diseases

  • DIFFERENTIATE

    by targeting emerging central disease biology nodes

  • IMPACT

    via selective depletion of pathogenic cells

Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology.

  • Granite Bio - GRT-001

    GRT-001

    Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.

  • Granite Bio – GRT-002

    GRT-002

    Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.

Two first-in-class therapeutic antibodies GRT-001 and GRT-002

Team:

Granite Bio Team:

Check out our lastest job posts:

Board of Directors:

Scientific Advisors:

  • Vishwa Deep Dixit

    Yale University
    Innate Immunity

  • Christopher Denton

    University College London
    Fibrosis

  • Jörg Distler

    Düsseldorf University
    Fibrosis

  • Erica Herzog

    Yale University
    Pulmonary Fibrosis

  • Brian Feagan

    Ontario, Canada
    Inflammatory Bowel Disease

  • Florian Rieder

    Cleveland Clinic
    Inflammatory Bowel Disease

  • Scott Brian Snapper

    Boston/Harvard University
    Inflammatory Bowel Disease

  • Portrait Carrie Sokol

    Carrie Sokol

    Boston/Harvard University
    Type-II Inflammation